(COV) Covivio - Ratings and Ratios
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0000064578
COV: Office, Housing, Hotels
Covivio SA (PA:COV) is a leading European real estate player with a rich history of partnerships and a deep understanding of user needs. The company specializes in creating vibrant, functional spaces that integrate work, travel, and living, while fostering sustainable relationships and well-being. With €23 billion in assets under management, Covivio supports companies, hotel brands, and territories in enhancing their attractiveness and achieving responsible performance. Its purpose-driven approach emphasizes sustainability and long-term value creation for stakeholders, including customers, shareholders, employees, and future generations.
Covivio operates across key European markets, focusing on prime office assets, hotels, and mixed-use developments. Its portfolio is characterized by high-quality properties in major cities, with a strong emphasis on sustainability and tenant experience. The company’s shares are listed on Euronext Paris (Compartment A) and are included in several major indices, including MSCI, SBF 120, CAC Mid100, and Euronext IEIF ‘SIIC France.’ Covivio also holds top-tier ESG ratings, such as CDP (A), GRESB (88/100, 5-Star), and MSCI (AAA), reflecting its commitment to environmental, social, and governance standards.
Based on the provided
From a fundamental perspective, Covivio’s market cap stands at €5.63 billion, with a trailing P/E of 80.71 and a forward P/E of 11.33, suggesting expectations of future earnings growth. The P/B ratio of 0.68 indicates undervaluation relative to book value, while the P/S ratio of 5.03 reflects a premium for its revenue streams. However, the negative RoE of -14.54% raises concerns about profitability.
3-Month Forecast: - Technical Outlook: Expect COV to test the €52-€55 range in the next quarter, driven by the bullish crossover of the 20-day and 50-day SMAs. Support is likely at €49.50 (SMA 20) and resistance at €53.50 (SMA 200). - Fundamental Outlook: The stock may experience upward pressure due to its attractive forward P/E and strong ESG profile, but the high trailing P/E and negative RoE could limit significant upside. - Target Price: €55.00 by Q4 2023, contingent on improving profitability and maintaining its ESG leadership.
Additional Sources for COV Stock
COV Stock Overview
Market Cap in USD | 6,476m |
Sector | Real Estate |
Industry | REIT - Diversified |
GiC Sub-Industry | Diversified REITs |
IPO / Inception |
COV Stock Ratings
Growth Rating | 0.36 |
Fundamental | -2.50 |
Dividend Rating | 27.5 |
Rel. Strength | -6.53 |
Analysts | - |
Fair Price Momentum | 47.85 EUR |
Fair Price DCF | 122.63 EUR |
COV Dividends
Dividend Yield 12m | 5.08% |
Yield on Cost 5y | 6.26% |
Annual Growth 5y | -7.22% |
Payout Consistency | 91.5% |
COV Growth Ratios
Growth Correlation 3m | -4.9% |
Growth Correlation 12m | 32.5% |
Growth Correlation 5y | -45.6% |
CAGR 5y | 4.59% |
CAGR/Max DD 5y | 0.09 |
Sharpe Ratio 12m | 0.68 |
Alpha | 2.28 |
Beta | 0.368 |
Volatility | 32.43% |
Current Volume | 103.5k |
Average Volume 20d | 145.9k |
As of May 08, 2025, the stock is trading at EUR 49.98 with a total of 103,479 shares traded.
Over the past week, the price has changed by +1.38%, over one month by +14.64%, over three months by +2.65% and over the past year by +7.42%.
Neither. Based on ValueRay Fundamental Analyses, Covivio is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -2.50 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COV as of May 2025 is 47.85. This means that COV is currently overvalued and has a potential downside of -4.26%.
Covivio has no consensus analysts rating.
According to ValueRays Forecast Model, COV Covivio will be worth about 51.7 in May 2026. The stock is currently trading at 49.98. This means that the stock has a potential upside of +3.4%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 59.5 | 19.1% |
Analysts Target Price | - | - |
ValueRay Target Price | 51.7 | 3.4% |